Jammu, July 22: In continuation to its efforts to curb the unlawful distribution and misuse of habit-forming drugs, Drugs and Food Control Organisation (D&FCO) J&K has taken stringent action against pharmaceutical establishments found violating the provisions of the Drugs and Cosmetics Act.A statement issued here that surprise inspections of the Pharma establishments were conducted and during the inspections, two pharma establishments were found indulging in clandestine purchase and sale of habit-forming pharmaceutical preparations, mainly comprising of Tapentadol and Pregabalin from neighbouring states without maintaining mandatory sale/purchase records.Accordingly, Drug sale licences of M/s Aatir Enterprises, Ganjiawra, Anantnag and M/s Pharma Plus Medicare, Kheora, Rajouri have been cancelled for indulging in unethical trade practices after issuing Show Cause Notices to them. State Drugs Controller Lotika Khajuria has reiterated that the Government of Jammu and Kashmir is committed to regulate the sale of scheduled drugs and strict compliance by all retail and wholesale drug license holders shall be ensured. Surprise inspection, digital tracking of medicine inventories and inter-agency coordination are being intensified. Strict penal action, including license cancellation and prosecution, will be ensured against those who endanger lives for profit.
D&FCO suspends licenses of two pharma stores for unethical practices

Sign Up For Daily Newsletter
Be keep up! Get the latest breaking news delivered straight to your inbox.
By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
Leave a Comment
Leave a Comment
Stay Connected
Latest News
Recent Posts
- IND vs ENG 4th Test Day 1 Stumps : India 264/4
- Dr Amit Wanchoo, NBT Director Call on LG Sinha to discuss Chinar Book Fest
- Rajya Sabha to hold discussion on Op Sindoor on July 29
- Congress reminds PM Modi of promise to restore J&K statehood
- CM Omar Abdullah directs monthly departmental reviews, stresses strict timeline enforcement under PSGA